Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 95

1.

Is %ΔSUVmax a useful indicator of survival in patients with advanced nonsmall-cell lung cancer?

Cistaro A, Quartuccio N, Mojtahedi A, Fania P, Filosso PL, Cucinotta M, Campennì A, Ficola U, Baldari S.

ScientificWorldJournal. 2013 Oct 9;2013:910957. doi: 10.1155/2013/910957. eCollection 2013.

PMID:
24228017
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Prognostic value of 18F-FDG uptake on positron emission tomography in patients with pathologic stage I non-small cell lung cancer.

Um SW, Kim H, Koh WJ, Suh GY, Chung MP, Kwon OJ, Choi JY, Han J, Lee KS, Kim J.

J Thorac Oncol. 2009 Nov;4(11):1331-6. doi: 10.1097/JTO.0b013e3181b6be3e.

PMID:
19701106
[PubMed - indexed for MEDLINE]
3.

A correlation study between maximum standardized uptake values and pathology and clinical staging in nonsmall cell lung cancer.

Lu P, Yu L, Li Y, Sun Y.

Nucl Med Commun. 2010 Jul;31(7):646-51.

PMID:
20545045
[PubMed - indexed for MEDLINE]
4.

Assessment of lung cancer response after nonoperative therapy: tumor diameter, bidimensional product, and volume. A serial CT scan-based study.

Werner-Wasik M, Xiao Y, Pequignot E, Curran WJ, Hauck W.

Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):56-61.

PMID:
11516851
[PubMed - indexed for MEDLINE]
5.

High FDG uptake predicts poorer survival in locally advanced nonsmall cell lung cancer patients undergoing curative radiotherapy, independently of tumor size.

Ulger S, Demirci NY, Eroglu FN, Cengiz HH, Tunc M, Tatci E, Yilmaz U, Cetin E, Avci E, Cengiz M.

J Cancer Res Clin Oncol. 2014 Mar;140(3):495-502. doi: 10.1007/s00432-014-1591-9. Epub 2014 Jan 29.

PMID:
24474555
[PubMed - indexed for MEDLINE]
6.

Differential diagnosis between (18)F-FDG-avid metastatic lymph nodes in non-small cell lung cancer and benign nodes on dual-time point PET/CT scan.

Suga K, Kawakami Y, Hiyama A, Sugi K, Okabe K, Matsumoto T, Ueda K, Tanaka N, Matsunaga N.

Ann Nucl Med. 2009 Aug;23(6):523-31. doi: 10.1007/s12149-009-0268-y. Epub 2009 May 15.

PMID:
19444550
[PubMed - indexed for MEDLINE]
7.

Initial partial response and stable disease according to RECIST indicate similar survival for chemotherapeutical patients with advanced non-small cell lung cancer.

He L, Teng Y, Jin B, Zhao M, Yu P, Hu X, Zhang J, Li S, Gao Y, Liu Y.

BMC Cancer. 2010 Dec 14;10:681. doi: 10.1186/1471-2407-10-681.

PMID:
21156055
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

The prognostic significance of maximum standardized uptake value of primary tumor in surgically treated non-small-cell lung cancer patients: analysis of 413 cases.

Billè A, Okiror L, Skanjeti A, Errico L, Arena V, Penna D, Ardissone F, Pelosi E.

Clin Lung Cancer. 2013 Mar;14(2):149-56. doi: 10.1016/j.cllc.2012.04.007. Epub 2012 Jun 7.

PMID:
22682667
[PubMed - indexed for MEDLINE]
9.

Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.

Satoh Y, Onishi H, Nambu A, Araki T.

Radiology. 2014 Jan;270(1):275-81. doi: 10.1148/radiol.13130652. Epub 2013 Oct 28.

PMID:
24029640
[PubMed - indexed for MEDLINE]
10.

Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection.

Hyun SH, Choi JY, Kim K, Kim J, Shim YM, Um SW, Kim H, Lee KH, Kim BT.

Ann Surg. 2013 Feb;257(2):364-70. doi: 10.1097/SLA.0b013e318262a6ec.

PMID:
22968069
[PubMed - indexed for MEDLINE]
11.

PET imaging of tumor hypoxia using 18F-fluoroazomycin arabinoside in stage III-IV non-small cell lung cancer patients.

Bollineni VR, Kerner GS, Pruim J, Steenbakkers RJ, Wiegman EM, Koole MJ, de Groot EH, Willemsen AT, Luurtsema G, Widder J, Groen HJ, Langendijk JA.

J Nucl Med. 2013 Aug;54(8):1175-80. doi: 10.2967/jnumed.112.115014. Epub 2013 Jun 10.

PMID:
23753185
[PubMed - indexed for MEDLINE]
Free Article
12.

The increment in standardized uptake value determined using dual-phase 18F-FDG PET is a promising prognostic factor in non-small-cell lung cancer.

Chen HH, Lee BF, Su WC, Lai YH, Chen HY, Guo HR, Yao WJ, Chiu NT.

Eur J Nucl Med Mol Imaging. 2013 Oct;40(10):1478-85. doi: 10.1007/s00259-013-2452-5. Epub 2013 Jun 7.

PMID:
23744342
[PubMed - indexed for MEDLINE]
13.

Measurement of tumor volume by PET to evaluate prognosis in patients with advanced non-small cell lung cancer treated by non-surgical therapy.

Yan H, Wang R, Zhao F, Zhu K, Jiang S, Zhao W, Feng R.

Acta Radiol. 2011 Jul 1;52(6):646-50. doi: 10.1258/ar.2011.100462. Epub 2011 Apr 20. Retraction in: Skjennald A. Acta Radiol. 2012 Jul;53(6):592.

PMID:
21508201
[PubMed - indexed for MEDLINE]
14.

Dual-time point 18F-FDG PET/CT scan for differentiation between 18F-FDG-avid non-small cell lung cancer and benign lesions.

Suga K, Kawakami Y, Hiyama A, Sugi K, Okabe K, Matsumoto T, Ueda K, Tanaka N, Matsunaga N.

Ann Nucl Med. 2009 Jul;23(5):427-35. doi: 10.1007/s12149-009-0260-6. Epub 2009 May 13.

PMID:
19437097
[PubMed - indexed for MEDLINE]
15.

The variation of prognostic significance of Maximum Standardized Uptake Value of [18F]-fluoro-2-deoxy-glucose positron emission tomography in different histological subtypes and pathological stages of surgically resected Non-Small Cell Lung Carcinoma.

Casali C, Cucca M, Rossi G, Barbieri F, Iacuzio L, Bagni B, Uliano M.

Lung Cancer. 2010 Aug;69(2):187-93. doi: 10.1016/j.lungcan.2009.10.015. Epub 2009 Nov 25.

PMID:
19942313
[PubMed - indexed for MEDLINE]
16.

SUVmax during 18FDG-PET scanning in small cell lung cancer: similar information as in non-small cell lung cancer?

van der Leest C, Smit EF, Baas J, Versteijlen RJ, van Walree N, Hoogsteden HC, Aerts JG.

Lung Cancer. 2012 Apr;76(1):67-71. doi: 10.1016/j.lungcan.2011.09.007. Epub 2011 Oct 11.

PMID:
21996089
[PubMed - indexed for MEDLINE]
17.

Study of pretreatment serum levels of HER-2/neu oncoprotein as a prognostic and predictive factor in patients with advanced nonsmall cell lung carcinoma.

Ardizzoni A, Cafferata MA, Paganuzzi M, Filiberti R, Marroni P, Neri M, Fontana V, Nicoló G, Perdelli L, Stampino CG, Rosso R, Puntoni R.

Cancer. 2001 Oct 1;92(7):1896-904.

PMID:
11745263
[PubMed - indexed for MEDLINE]
18.

Predictive value of primary fluorine-18 fluorodeoxyglucose standard uptake value for a better choice of systematic nodal dissection or sampling in clinical stage ia non--small-cell lung cancer.

Li X, Zhang H, Xing L, Xu X, Xie P, Ma H, Zhang L, Chen M, Sun X, Xu W, Chen L, Yu J.

Clin Lung Cancer. 2013 Sep;14(5):568-73. doi: 10.1016/j.cllc.2013.02.002. Epub 2013 Jul 5.

PMID:
23835164
[PubMed - indexed for MEDLINE]
19.

Does response to induction chemotherapy predict survival for locally advanced non-small-cell lung cancer? Secondary analysis of RTOG 8804/8808.

McAleer MF, Moughan J, Byhardt RW, Cox JD, Sause WT, Komaki R.

Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3):802-8. doi: 10.1016/j.ijrobp.2009.02.053. Epub 2009 Jun 18.

PMID:
19540055
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk